Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

France Heart Failure Drugs Market

ID: MRFR/MED/50691-HCR
200 Pages
Vikita Thakur
Last Updated: February 06, 2026

France Heart Failure Drugs Market Research Report: Size, Share, Trend Analysis By Drug Class (Angiotensin-Converting Enzyme Inhibitors, Beta Blockers, Diuretics, Angiotensin II Receptor Blockers, Mineralocorticoid Receptor Antagonists), By Administration Route (Oral, Intravenous, Subcutaneous), By Patient Type (Acute Heart Failure, Chronic Heart Failure, Heart Failure with Preserved Ejection Fraction) and By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

France Heart Failure Drugs Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Construction, BY Drug Class (USD Million)
  49.     4.1.1 Angiotensin-Converting Enzyme Inhibitors
  50.     4.1.2 Beta Blockers
  51.     4.1.3 Diuretics
  52.     4.1.4 Angiotensin II Receptor Blockers
  53.     4.1.5 Mineralocorticoid Receptor Antagonists
  54.   4.2 Construction, BY Administration Route (USD Million)
  55.     4.2.1 Oral
  56.     4.2.2 Intravenous
  57.     4.2.3 Subcutaneous
  58.   4.3 Construction, BY Patient Type (USD Million)
  59.     4.3.1 Acute Heart Failure
  60.     4.3.2 Chronic Heart Failure
  61.     4.3.3 Heart Failure with Preserved Ejection Fraction
  62.   4.4 Construction, BY Distribution Channel (USD Million)
  63.     4.4.1 Hospital Pharmacy
  64.     4.4.2 Retail Pharmacy
  65.     4.4.3 Online Pharmacy
  66. 5 SECTION V: COMPETITIVE ANALYSIS
  67.   5.1 Competitive Landscape
  68.     5.1.1 Overview
  69.     5.1.2 Competitive Analysis
  70.     5.1.3 Market share Analysis
  71.     5.1.4 Major Growth Strategy in the Construction
  72.     5.1.5 Competitive Benchmarking
  73.     5.1.6 Leading Players in Terms of Number of Developments in the Construction
  74.     5.1.7 Key developments and growth strategies
  75.       5.1.7.1 New Product Launch/Service Deployment
  76.       5.1.7.2 Merger & Acquisitions
  77.       5.1.7.3 Joint Ventures
  78.     5.1.8 Major Players Financial Matrix
  79.       5.1.8.1 Sales and Operating Income
  80.       5.1.8.2 Major Players R&D Expenditure. 2023
  81.   5.2 Company Profiles
  82.     5.2.1 Novartis (CH)
  83.       5.2.1.1 Financial Overview
  84.       5.2.1.2 Products Offered
  85.       5.2.1.3 Key Developments
  86.       5.2.1.4 SWOT Analysis
  87.       5.2.1.5 Key Strategies
  88.     5.2.2 Bristol-Myers Squibb (US)
  89.       5.2.2.1 Financial Overview
  90.       5.2.2.2 Products Offered
  91.       5.2.2.3 Key Developments
  92.       5.2.2.4 SWOT Analysis
  93.       5.2.2.5 Key Strategies
  94.     5.2.3 Merck & Co. (US)
  95.       5.2.3.1 Financial Overview
  96.       5.2.3.2 Products Offered
  97.       5.2.3.3 Key Developments
  98.       5.2.3.4 SWOT Analysis
  99.       5.2.3.5 Key Strategies
  100.     5.2.4 Amgen (US)
  101.       5.2.4.1 Financial Overview
  102.       5.2.4.2 Products Offered
  103.       5.2.4.3 Key Developments
  104.       5.2.4.4 SWOT Analysis
  105.       5.2.4.5 Key Strategies
  106.     5.2.5 Bayer (DE)
  107.       5.2.5.1 Financial Overview
  108.       5.2.5.2 Products Offered
  109.       5.2.5.3 Key Developments
  110.       5.2.5.4 SWOT Analysis
  111.       5.2.5.5 Key Strategies
  112.     5.2.6 Pfizer (US)
  113.       5.2.6.1 Financial Overview
  114.       5.2.6.2 Products Offered
  115.       5.2.6.3 Key Developments
  116.       5.2.6.4 SWOT Analysis
  117.       5.2.6.5 Key Strategies
  118.     5.2.7 Gilead Sciences (US)
  119.       5.2.7.1 Financial Overview
  120.       5.2.7.2 Products Offered
  121.       5.2.7.3 Key Developments
  122.       5.2.7.4 SWOT Analysis
  123.       5.2.7.5 Key Strategies
  124.     5.2.8 AstraZeneca (GB)
  125.       5.2.8.1 Financial Overview
  126.       5.2.8.2 Products Offered
  127.       5.2.8.3 Key Developments
  128.       5.2.8.4 SWOT Analysis
  129.       5.2.8.5 Key Strategies
  130.   5.3 Appendix
  131.     5.3.1 References
  132.     5.3.2 Related Reports
  133. 6 LIST OF FIGURES
  134.   6.1 MARKET SYNOPSIS
  135.   6.2 FRANCE MARKET ANALYSIS BY DRUG CLASS
  136.   6.3 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE
  137.   6.4 FRANCE MARKET ANALYSIS BY PATIENT TYPE
  138.   6.5 FRANCE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  139.   6.6 KEY BUYING CRITERIA OF CONSTRUCTION
  140.   6.7 RESEARCH PROCESS OF MRFR
  141.   6.8 DRO ANALYSIS OF CONSTRUCTION
  142.   6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
  143.   6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
  144.   6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
  145.   6.12 CONSTRUCTION, BY DRUG CLASS, 2024 (% SHARE)
  146.   6.13 CONSTRUCTION, BY DRUG CLASS, 2024 TO 2035 (USD Million)
  147.   6.14 CONSTRUCTION, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
  148.   6.15 CONSTRUCTION, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Million)
  149.   6.16 CONSTRUCTION, BY PATIENT TYPE, 2024 (% SHARE)
  150.   6.17 CONSTRUCTION, BY PATIENT TYPE, 2024 TO 2035 (USD Million)
  151.   6.18 CONSTRUCTION, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
  152.   6.19 CONSTRUCTION, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
  153.   6.20 BENCHMARKING OF MAJOR COMPETITORS
  154. 7 LIST OF TABLES
  155.   7.1 LIST OF ASSUMPTIONS
  156.     7.1.1
  157.   7.2 France MARKET SIZE ESTIMATES; FORECAST
  158.     7.2.1 BY DRUG CLASS, 2025-2035 (USD Million)
  159.     7.2.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
  160.     7.2.3 BY PATIENT TYPE, 2025-2035 (USD Million)
  161.     7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
  162.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  163.     7.3.1
  164.   7.4 ACQUISITION/PARTNERSHIP
  165.     7.4.1

France Construction Market Segmentation

Construction By Drug Class (USD Million, 2025-2035)

  • Angiotensin-Converting Enzyme Inhibitors
  • Beta Blockers
  • Diuretics
  • Angiotensin II Receptor Blockers
  • Mineralocorticoid Receptor Antagonists

Construction By Administration Route (USD Million, 2025-2035)

  • Oral
  • Intravenous
  • Subcutaneous

Construction By Patient Type (USD Million, 2025-2035)

  • Acute Heart Failure
  • Chronic Heart Failure
  • Heart Failure with Preserved Ejection Fraction

Construction By Distribution Channel (USD Million, 2025-2035)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓